Search tips
Search criteria 


Logo of skullbasesurgInstructions for AuthorsSubscribe to Skull BaseAbout Skull BaseEditorial BoardThieme Medical PublishingSkull Base An Interdisciplinary Approach ...
Skull base surgery. 1994 July; 4(3): 122–126.
PMCID: PMC1661804

Highly Selective Infusions of Supradose Cisplatin for Cranial Base Malignancies


Treatment results for malignant skull base lesions may be improved with combined modality therapy. Using a novel drug infusion technique that capitalizes on the pharmacodynamic cisplatin-neutralizing properties of thiosulfate, 14 patients (6 untreated, 8 recurrent) received cisplatin (120 to 200 mg/m2 for 1 to 4 weeks × 2-4 cycles) as part of a multimodality treatment program. Histology included squamous cell carcinoma, 11 patients (8 upper aerodigestive tract, 3 cutaneous); sarcoma, 2 patients (malignant fibrous histiocytoma, synovial cell sarcoma); and salivary gland cancer, 1 patient. The lesions involved the lateral skull base (12 patients) and the anterior (2 patients).

Dose intensities for cisplatin were between 33.3 and 200 mg/m2/wk. Major responses occurred in 9/14 patients (64.3%), 3 of whom had complete responses. Drug toxicity, occurring in 11 patients, was mild and there were no significant complications as a result of the infusions. Eleven patients subsequently underwent surgical resections. The mean survival time is 23.3 months. Eight patients are alive without disease, 2 alive with disease, and 4 are dead of disease.

The effectiveness of this highly selective supradose cisplatin infusion technique and its low morbidity support continued investigations of its application to patients with cranial base malignancies.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • LEDERMAN M. MALIGNANT TUMOURS OF THE EAR. J Laryngol Otol. 1965 Feb;79:85–119. [PubMed]
  • Goodwin WJ, Jesse RH. Malignant neoplasms of the external auditory canal and temporal bone. Arch Otolaryngol. 1980 Nov;106(11):675–679. [PubMed]
  • Conley J, Schuller DE. Malignancies of the ear. Laryngoscope. 1976 Aug;86(8):1147–1163. [PubMed]
  • Wang CC. Radiation therapy in the management of carcinoma of the external auditory canal, middle ear, or mastoid. Radiology. 1975 Sep;116(3):713–715. [PubMed]
  • Wagenfeld DJ, Keane T, van Nostrand AW, Bryce DP. Primary carcinoma involving the temporal bone: analysis of twenty-five cases. Laryngoscope. 1980 Jun;90(6 Pt 1):912–919. [PubMed]
  • Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope. 1988 Nov;98(11):1205–1211. [PubMed]
  • Kun LE, Toohill RJ, Holoye PY, Duncavage JA, Byhardt RW, Ritch PS, Grossman TW, Hoffmann RG, Cox JD, Malin T. A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract. Int J Radiat Oncol Biol Phys. 1986 Feb;12(2):173–178. [PubMed]
  • Dreyfuss AI, Clark JR, Wright JE, Norris CM, Jr, Busse PM, Lucarini JW, Fallon BG, Casey D, Andersen JW, Klein R, et al. Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med. 1990 Feb 1;112(3):167–172. [PubMed]
  • Sessions RB, Lehane DE, Smith RJ, Bryan RN, Suen JY. Intra-arterial cisplatin treatment of adenoid cystic carcinoma. Arch Otolaryngol. 1982 Apr;108(4):221–224. [PubMed]
  • Robbins KT, Storniolo AM, Kerber C, Seagren S, Berson A, Howell SB. Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck. 1992 Sep-Oct;14(5):364–371. [PubMed]
  • Lee YY, Dimery IW, Van Tassel P, De Pena C, Blacklock JB, Goepfert H. Superselective intra-arterial chemotherapy of advanced paranasal sinus tumors. Arch Otolaryngol Head Neck Surg. 1989 Apr;115(4):503–511. [PubMed]
  • Forastiere AA, Baker SR, Wheeler R, Medvec BR. Intra-arterial cisplatin and FUDR in advanced malignancies confined to the head and neck. J Clin Oncol. 1987 Oct;5(10):1601–1606. [PubMed]
  • Mortimer JE, Taylor ME, Schulman S, Cummings C, Weymuller E, Jr, Laramore G. Feasibility and efficacy of weekly intraarterial cisplatin in locally advanced (stage III and IV) head and neck cancers. J Clin Oncol. 1988 Jun;6(6):969–975. [PubMed]
  • Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982 Dec;97(6):845–851. [PubMed]
  • Shea M, Koziol JA, Howell SB. Kinetics of sodium thiosulfate, a cisplatin neutralizer. Clin Pharmacol Ther. 1984 Mar;35(3):419–425. [PubMed]
  • Fu KK. Biological basis for the interaction of chemotherapeutic agents and radiation therapy. Cancer. 1985 May 1;55(9 Suppl):2123–2130. [PubMed]
  • Tannock IF, Rotin D. Mechanisms of interaction between radiation and drugs with potential for improvements in therapy. NCI Monogr. 1988;(6):77–83. [PubMed]
  • Dewit L. Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):403–426. [PubMed]

Articles from Skull Base Surgery are provided here courtesy of Thieme Medical Publishers